Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis

Climacteric

Volumn 13, Issue 1, 2010, Pages 72-83

  Mizunuma, H ^a   Taketani, Y ^b   Ohta, H ^c   Honjo, H ^d   Gorai, I ^e   Itabashi, A ^f   Shiraki, M ^g  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Aiseikai Yamashina Hospital   (Japan)

^e International University of Health and Welfare   (Japan)

^f Saitama Center for Bone Research   (Japan)

^g Research Institute and Practice for Involutional Diseases   (Japan)

Author keywords

Estradiol; Japanese; Oral; Osteoporosis; Postmenopausal

Indexed keywords

CALCIUM; COLECALCIFEROL; ESTRADIOL; LEVONORGESTREL; PLACEBO;

ADULT; AGED; ARTICLE; BACKACHE; BONE DENSITY; BREAST DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENITAL BLEEDING; HEART ARRHYTHMIA; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MASTALGIA; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STOMACH CANCER; VAGINA BLEEDING;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; JAPAN; LEVONORGESTREL; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PLACEBOS;

EID: 75149143997     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130902926910     Document Type: Article

References (33)

1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767
2. Genazzani AR, Gambacciani M, Schneider HPG, et al. Postmenopausal osteoporosis: therapeutic options. International Menopause Society expert workshop. Climacteric 2005;8: 99-109
3. Cooper C, Campion C, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-289
4. Fujiwara S. Epidemiology of osteoporosis in Japan. J Bone Miner Metab 2005;23(Suppl): 81-83
5. Yoshimura N, Suzuki T, Hosoi T, et al. Epidemiology of hip fracture in Japan: incidence and risk factors. J Bone Miner Metab 2005; 23(Suppl):78-80
6. Skouby SO, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51:8-14
7. Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Public Health Service, 2004
8. Birkhäuser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108-123
9. Cranney A, Wells GA. Hormone replacement therapy for postmenopausal osteoporosis. Clin Geriatr Med 2003;19:361-370
10. Ohta H. [Hormone replacement therapy and osteoporosis from the perspective of evidencebased medicine.] Clin Calcium 2002;12:43-48
11. Mizunuma H. [Treatment of osteoporosis with estrogen.] Nippon Rinsho 2004;62(S2):397-403
12. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13: 340-367
13. Jilka RL, Takahashi K, Munshi M, et al. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 1998;101:1942-1950
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
15. Cauley JA, Robbins J, Chen Z, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290: 1729-1738
16. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602
17. Tan D, Darmasetiawan S, Haines CJ, et al., Expert Panel on Menopause in Asian Women. Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. Climacteric 2006;9: 146-151
18. Nozawa S. [Response to HRT in Japanese women and continuation rate.] Proceedings of the Research Project on Aging and Health 1995; 6:338-342
19. Mizunuma H. [Studies on the natural history and prevention of postmenopausal bone loss in Japanese women.] J Jpn Menopause Soc 1999;7: 34-41
20. Nishizawa Y, Nakamura T, Ohata H, et al. Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis: Japan Osteoporosis Society. Guidelines on the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 2001;19:338-344
21. Cranney A, Guyatt G Griffith L, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Metaanalyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578
22. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-2897
23. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
24. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the Women's International Study of long Duration Oestrogen after Menopause (WISDOM): a randomized controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335: 239-250
25. Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas 1997;27:69-76
26. Gorai I, Chaki O, Taguchi Y, et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcif Tissue Int 1999;65: 16-22
27. Cummings S, Browner W, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998;339:733-738 (Pubitemid 28417356)
28. Ettinger B, Pressman A, Sklarin P, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998;83:2239-2243
29. Simon JA, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007; 109:588-596
30. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451
31. Lee BS, Kang BM, Yoon BK, et al. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas 2007;57:361-369
32. Doren M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod 2003;18: 1737-1746
33. Pitkin J, Rees M, Gray S, et al. Managing the menopause: British Menopause Society Consensus Statement on Hormone Replacement Therapy 2005. J Br Menopause Soc 2005;11: 152-156